Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

12.21
-0.5300-4.16%
Pre-market: 12.12-0.0900-0.74%08:47 EDT
Volume:4.93M
Turnover:61.02M
Market Cap:1.71B
PE:-3.65
High:12.82
Open:12.50
Low:12.19
Close:12.74
52wk High:28.25
52wk Low:7.95
Shares:140.00M
Float Shares:137.56M
Volume Ratio:1.61
T/O Rate:3.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3456
EPS(LYR):-3.8100
ROE:-55.44%
ROA:-30.14%
PB:2.35
PE(LYR):-3.20

Loading ...

Intellia Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $25 From $30

THOMSON REUTERS
·
May 13

U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic

Reuters
·
May 13

Intellia Therapeutics (NTLA) Quarterly Loss Near US$96 Million Tests Bullish Profitability Timeline

Simply Wall St.
·
May 13

Intellia Therapeutics Price Target Maintained With a $12.00/Share by Wedbush

Dow Jones
·
May 12

RBC Capital Keeps Their Hold Rating on Intellia Therapeutics (NTLA)

TIPRANKS
·
May 12

Intellia Therapeutics price target lowered to $49 from $58 at Canaccord

TIPRANKS
·
May 12

Intellia Therapeutics reports Q1 EPS (81c), consensus (90c)

TIPRANKS
·
May 12

Myles Minter Reiterates Buy on Intellia (NTLA), Citing Extended Cash Runway and Strong Phase III Data for Lonvoguran Ziclumeran

TIPRANKS
·
May 12

Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE), Intellia Therapeutics (NTLA) and Corvus Pharmaceuticals (CRVS)

TIPRANKS
·
May 11

Intellia Therapeutics Q1 Loss Narrows, Revenue Falls

MT Newswires Live
·
May 11

Intellia Therapeutics Q1 net loss narrows on lower R&D spending

Reuters
·
May 11

Intellia Therapeutics Q1 EPS $(0.81) Beats $(0.90) Estimate, Sales $15.048M Beat $14.793M Estimate

Benzinga Earnings
·
May 11

Earnings Flash (NTLA) Intellia Therapeutics Posts Q1 Net Loss $0.81 a Share, vs. FactSet Est of $0.91 Loss

MT Newswires Live
·
May 11

BRIEF-Intellia Therapeutics Q1 Net Income USD -96.231 Million

Reuters
·
May 11

Intellia Q1 FY26 net loss narrows 15.9% to $96.2 million

Reuters
·
May 11

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

THOMSON REUTERS
·
May 11

Intellia Therapeutics Q1 Basic EPS USD -0.81

THOMSON REUTERS
·
May 11

Is Intellia Therapeutics (NTLA) Pricing Reflect Its Gene Editing Potential After Recent Price Surge

Simply Wall St.
·
May 09

Intellia Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 05

Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics today

TIPRANKS
·
May 02